Biomedicinal Information Research Center, National Institute of Advanced Industrial Science and Technology, Aomi, Koto-ku, Tokyo, Japan.
Cancer Lett. 2011 Jan 28;300(2):189-96. doi: 10.1016/j.canlet.2010.10.005. Epub 2010 Nov 4.
Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with a poor prognosis. Thus, novel therapeutic agents need to be developed for treating it. We recently reported the isolation of the novel anti-MPM compound designated as JBIR-23 from Streptomyces sp. AK-AB27. In this study, JBIR-23 exerted its cytotoxic effect on MPM cells by promotion of tubulin polymerization and G₂/M arrest, which was followed by apoptosis induction via the caspase pathway through phosphorylation of p38 mitogen-activated protein kinase and c-jun N-terminal kinase. Furthermore, in vivo analysis demonstrated that JBIR-23 prevented tumor growth in tumor-bearing nude mice without evident side effects.
恶性胸膜间皮瘤（MPM）是一种侵袭性强、预后差的肿瘤。因此，需要开发新的治疗药物来治疗它。我们最近报道了从链霉菌 AK-AB27 中分离出一种新型抗 MPM 化合物，命名为 JBIR-23。在这项研究中，JBIR-23 通过促进微管蛋白聚合和 G₂/M 期阻滞发挥其对 MPM 细胞的细胞毒性作用，随后通过 caspase 途径诱导细胞凋亡，这是通过磷酸化 p38 丝裂原活化蛋白激酶和 c-jun N 端激酶实现的。此外，体内分析表明，JBIR-23 可防止荷瘤裸鼠的肿瘤生长，且无明显副作用。
